DIAGNOS Inc.
Technology, Healthcare,
Mining,
Industrial
TSX-V: ADK, OTC: DGNOF,
http://www.DIAGNOS.ca
|
Prices |
Share:
C$0.12 |
MCap: ~C$20M |
On: 09/20/2017 |
History |
52-Week:
C$0.04–C$0.20 |
|
|
Prices |
Shares O/S:
~170 million |
Fully D.~200M |
|
|
|
A few months ago Market Equities
Research Group identified DIAGNOS Inc. in a research
report with several potential catalysts that exist
near-term with potential to result in $150 million
market cap ($1 /share) for ADK. A copy of that research
report may be viewed
here. We reiterate that price target as a near-term
(12-month) target, on the way to substantially higher
valuations from there.
Look for confirmation of
diabetes screening targets being met, announcements of
new deals, partner developments, earnings, and further
developments in platform targeting cardiovascular
disease as catalysts.
Fig. 1
Retinal image enhanced with DIAGNOS software, prepped
for A.I. auto-detection of pathology & lesion classification.
Using artificial intelligence in healthcare saves
government and healthcare services money by preventing
debilitating blindness in at-risk populations.
|
DIAGNOS Inc. (TSX-V:
ADK) (US
Listing: DGNOF) (Frankfurt: 4D4)
is a Canadian-based healthcare software technology company, its
'Computer Assisted Retinal Analysis' (CARA) business has been
successfully applying
artificial intelligence in the diabetes market for several years via non-invasively
identifying patients at risk of vision loss. The Company is active in 15 countries in total
for installations of its CARA technology platform worldwide, this
number and related metrics are only just getting started with the
company in the early stages of a vertical growth trajectory. On
September 19, 2017 the Company announced an expansion of its
platform into early detection of Cardiovascular Disease; click to
view release "DIAGNOS
Provides Timelines on Cardiovascular Disease (CVD) Prevention Test
Development and Commercialization Plans".
DIAGNOS Inc.'s proprietary artificial intelligence algos
continually learn and refine analytics from large data
sets. If results from the newly announced move into
cardiovascular disease (CVD) are anything similar to the
success DIAGNOS has achieved with early detection of
diabetes, it will affirm the Company has effectively
cracked the key to early detection of heart disease via
computer assisted retinal analysis, and the potential
implications for shareholders of ADK.V are enormous,
with dramatic upward share price appreciation being a
certainty.
The newly announced calibration of the application for
CVD will be done simultaneously in 4 countries (Algeria,
Canada, Mexico and United States) with a minimum of
1,000 in each country with the support of 22
cardiologists. This will enable Diagnos to insure the
sustainability of its solution worldwide.
Diagnos' current market cap (currently ~$20 million
Canadian for ADK.V trading at 12 cents) is miniscule
compared to its potential. Success in early detection of
heart disease in such a non-invasive manner (for the
patient), and disruptive to the marketplace, similar to
that which Diagnos Inc. has already proven it is able to
do for diabetes, will quickly result in the Company
being a primary go-to service in a massive market place
that currently spends near US$400 Billion a year in
drugs and services for cardiovascular and stroke issues.
|
Excerpt of September 19,
2017 Company news release:
DIAGNOS Provides Timelines on Cardiovascular
Disease (CVD) Prevention Test Development
and Commercialization Plans
Cardiovascular Artery Disease (CAD)
prevention score development six to twelve
months ahead of schedule; commercial launch
in first half of 2018
BROSSARD, QUEBEC--(Marketwired - Sept.
19, 2017) - DIAGNOS
Inc. ("DIAGNOS" or "the Corporation") (TSX
VENTURE:ADK)(OTCQB:DGNOF), a leader in
early detection of critical health
issues through the use of its FLAIRE platform
based on Artificial Intelligence (AI),
announces today a development of new
cardiovascular risk score, that will
enable the early detection of this
critical disease by its CARA platform.
The calibration of our
application will be done simultaneously
in 4 countries with a minimum of 1,000
in each country with the support of 22
cardiologists. This will enable us to
insure the sustainability of our
solution worldwide. The partners that
will be collaborating with DIAGNOS are
in Algeria, Canada, Mexico and United
States.
"We're
at the final development stage and ready
to evaluate the effectiveness of our
automatic grading for the new risk score
test CARA Cardio. Continually, we hear
from physicians and health insurers that
our screening tests are very much needed
to detect at early stage the
cardiovascular anomalies. Our preventive
cardiovascular risk score test will be
used to prospectively predict and
monitor the cardiovascular artery
diseases. Diagnos' AI will automatically
grade the retinal microcirculation state
to generate this score. At regular
interval, we will monitor the patients
using the same test"
said Dr Hadi Chakor, Diagnos Chief
Medical Officer. "Our
test will precede painful and stressing
invasive procedure that may cause costly
late complication."
While coronary
angiography remains the gold standard to
confirm the presence and severity of
coronary atherosclerosis, issues of
accessibility and cost-effectiveness of
the procedure have spurred the need to
investigate novel imaging modalities.
Diagnos' Cardio prevention test is based
on existing studies (Atherosclerosis
Risk in Communities Study ''ARIC''
(Circulation 2016), The Rotterdam Study
(Neurology. 2006), The Beaver Dam Eye
Study. (Ophthalmology, 2012),
multi-ethnic study of atherosclerosis
(Hypertension, 2008) et al…) that have
demonstrated an anatomical correlation
between the coronary macro-vascular
supply and the micro-vascular blood
supply to the retina. Theses anomalies
are strongly associated with
cardiovascular risk factors such: as
dyslipidemia, diabetes, smoking
hypertension and a positive family
history of premature CAD.
We are expecting to
complete this final step of test
development process during the next 6
months. In using our CARA telemedicine
platform, we've shorten our go to market
timeline by 12 months.
"Our test will address
one of the more pressing needs in
cardiology and preventive medicine field
to decrease the socioeconomic burden and
complication cost of this pathology.
This approach should complement public
actions to reduce community risk factor
levels and promote a healthy lifestyle.
The simplicity and costly effectiveness
makes this score test with very
promising future to predict
cardiovascular disease. The market size
and cost associated with CVD & stroke
yearly is $386 billions per year (Heidenreich,
et al., 2012." said
André Larente, CEO, Diagnos.
About CARA
CARA is a tele-ophthalmology
platform that integrates with existing
equipment (hardware and software) and
processes at the point of care (POC) and
comprises: image upload, image
enhancement automated pre-screening,
grading by a specialist, and referral to
a specialist. CARA's Artificial
Intelligence, based on FLAIRE technology,
image enhancement algorithms make
standard retinal images sharper,
clearer, and easier to read. CARA is
accessible securely over the internet,
and is compatible with all recognized
image formats and brands of fundus
cameras, and is EMR compatible. CARA is
a cost-effective tool for screening
large numbers of patients, in real time
and has been approved by regulatory
authorities including Health Canada, US
Food and Drug Administration, the
European Union and others. ...
...Click
here for full
copy from source
|
Market Equities Research Group
pointed out in its
June research report that DIAGNOS' foray into early
detection of Cardiovascular Disease has the potential to
be a MAJOR company maker. The retinal vasculature
is proposed as an easily and safely measured surrogate
for the coronary circulation. It is hypothesized that
because retinal vessels are approximately the same
magnitude as coronary microvasculature (~100250μm in
diameter) they can serve as representative of processes
occurring in coronary microvessels, and therefore serve
as a marker for subclinical or microvascular coronary
disease. Over the last 8-10 years, multiple large,
prospective studies examining the relationship between
retinal vascular changes and clinical endpoints of
coronary disease has provided strong evidence for a
positive correlation between the two. It is known that
abnormalities in retinal images can potentially provide
useful information about clinical and sub-clinical (not
severe enough to present definite or readily observable
symptoms) cerebrovascular, cardiovascular, and metabolic
health of the patient. There are therefore advantages of
using digital image analysis to quantify the extent of
retinal pathology in vascular diseases, diabetic
retinopathy (DR), age-related maculopathy and other
conditions.
With or without this new foray into CVD, DIAGNOS Inc. (TSX-V:
ADK) has potential to readily reach in our $1/share
price target within 12 months based on DIAGNOS' current
adoption rate for its CARA platform targeting diabetes
alone.
|
------ ------ ------ ------ ------ ------
------ ------ ------
We have identified the
following additional research links for further DD on DIAGNOS Inc.
Q2 research report:
http://sectornewswire.com/MarketEquitiesResearch-ADK-June-2017.pdf
Recent Technology
Journal article:
http://www.technologymarketwatch.com/adk.htm
------ ------
------ ------ ------
------
------ ------
------
#
# #
This bulletin may contain
forward-looking statements regarding future events that involve risk and
uncertainties. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual events or
results. Articles, excerpts, commentary and reviews herein are for information
purposes and are not solicitations to buy or sell any of the securities
mentioned.
Contact information:
Simon Levinson,
Editor in Chief
and Fredrick William
Market Equities Research Group
s.levinson@marketequitiesresearch.com
|
|
|
xxxx xxxx xxxx xxxx xxxx
xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx
xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx
xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx
xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx
Content found herein is not investment
advise see
Terms of Use, Disclaimer, & Disclosure
©2003 - 2017 Market Equities Research
Group
All rights reserved. |
MarketEquitiesResearch.com |
Terms
of Use, Disclaimer, & Disclosure
Privacy
Client
login
Home |
|
|
|
|
|